Axiom Bio

Axiom helps scientists eliminate molecular toxicity by providing the most accurate and affordable predictive models. Our proprietary dataset includes more than 100,000 molecules tested in pooled primary human liver cells, tens of thousands of molecules with pharmacokinetic measurements, and thousands of molecules with curated clinical outcome data. Axiom's AI models offer higher accuracy than advanced in vitro systems like 3d spheroids, deep mechanistic understanding which untangles mitochondrial toxicity, ER stress, ROS formation, cytotoxicity, and more, and precise risk assessment for any molecule at relevant clinical dosage and clinical exposure levels. Our models remove the need for costly physical experiments, giving more accurate and cheaper toxicity assessments, and empowering scientists to make better-informed decisions and bring safer drugs to the clinic.

Website

http://axi.om/

External link for Axiom Bio

Industry

Biotechnology Research

Company size

11-50 employees

Headquarters

San Francisco, CA

Type

Privately Held

Founded

2024